Project Name: Southern Health & Social Care Trust Lipid Optimisation Collaborative Working Project

Project Summary: 

The objective of this Collaborative Working Project is to redesign, refocus and improve the Cardiac Rehabilitation service in the Southern Health & Social Care Trust through the recruitment of three 0.5 full time equivalent (“FTE”) cardiac rehab nurses band 7, two 0.5 FTE healthcare assistants band 3 and one 0.5 FTE administrator band 3 to provide 60 additional clinical hours per week to implement and pilot the following to improve patient outcomes in the CW Partners region:

  • Providing equitable access to risk screening
  • Designing enhanced risk identification
  • Improving risk stratification
  • Creating personalised risk management plans
  • Continuous monitoring and improvement
  • Enhancing a collaborative approach to patient care   
  • Piloting implementation and business case development

Expected Benefits: 

Anticipated Benefits for Patients

  • Improved access to care leading to optimal management of CV risk factors and treatment pathway.    
  • Enhanced experience around CV risk with ongoing management of the condition. 
  • Reduced waiting time of initial assessment, reviews, commencing class program or home based program.   
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events
  • Levelling health inequalities within the Trust 

Anticipated Benefits for CW Partner

  • Increased proportion of secondary care CV patients undergoing optimisation
  • Increased proportion of CV patients receiving expert and timely review
  • Reduction in CV events in patients who have received a review and medicines optimisation, and leading to fewer re-admissions.
  • Increased proportion of patients receiving guideline-directed pharmacotherapy  
  • Reduce healthcare inequalities. Alleviate current in-service post code lottery of care provided. 

Anticipated benefits for Novartis

  • Insights into risk factor screening and subsequent management of high-risk patients (including LDL, FH and Lp(a)). 
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities    
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation  

Start Date & Duration: July 2025 for 16 months

FA-11473085 | July 2025